Adverse events (randomisation to post‐treatment) · children and adolescents with anxiety disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effect/event(s) ‐ serious adverse events · schizophrenia or related disorders
It is very uncertain whether modafinil changes adverse effect/event(s) ‐ serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events not measured · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major adverse cardiac and cerebrovascular events · people with or without existing CVD, men and women
It is very uncertain whether higher polyunsaturated fatty acid (PUFA) changes major adverse cardiac and cerebrovascular events compared with lower PUFA (very low certainty).
1 finding from 1 review
Adverse events (punctate epithelial keratopathy) · adults with dry eye syndrome
Summary of findings: punctal plugs showed no clear difference in adverse events (punctate epithelial keratopathy) compared with artificial tears (low certainty).
1 finding from 1 review
Specific adverse events · women with PMS
1 finding from 1 review
Withdrawals due to adverse events · women with PMS
It is very uncertain whether dose comparison: oestrogen 100 µg patch changes adverse events ‐ withdrawal rates over 8 months' compared with 200 µg patch plus progestogen (very low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · patients with non‐muscle invasive bladder cancer
Intravesically administered BCG alternating with IFN‐α showed no clear difference in discontinuation of therapy due to adverse events compared with intravesically administered BCG alone (low certainty).
1 finding from 1 review
Adverse events other than hypoglycaemic episodes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events other than hypoglycaemic episodes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events ‐ serious ocular events at 1 year · people with age‐related macular degeneration
The intervention showed no clear difference in adverse events ‐ serious ocular events at 1 year (moderate certainty).
1 finding from 1 review
Participant‐assessed adverse events (short‐term) · people with acne scars
The review found no eligible studies for this question.
1 finding from 1 review
Participant‐assessed adverse events (short‐term) · people with acne scars
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
It is very uncertain whether infliximab changes withdrawal due to adverse events (at 32‐54 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE patients
Corticosteroids may leads to lower withdrawals due to adverse events (2 to 12 weeks) compared with placebo (low certainty).
1 finding from 1 review
Number of participants reporting an adverse event · adults with early (stage 1 to 3) non‐diabetic CKD
Angiotensin‐converting enzyme inhibitors may leads to higher adverse events: number reporting an adverse event compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Death and serious adverse events, including falls · participants after stroke
1 finding from 1 review
Intervention not reported
Death and serious adverse events, including falls · participants after stroke
1 finding from 1 review
Withdrawals due to adverse events · adults (aged 18+) with colorectal cancer
It is very uncertain whether adjunctive Coriolus versicolor changes withdrawal from treatment due to adverse events ‐ compared with no adjunctive treatment (very low certainty).
1 finding from 1 review
Adverse events (7 to 24 months post intervention) · women with perinatal depression
1 finding from 1 review